Nuzenio

Innate Pharma Enters

Innate Pharma Enters news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 15 latest news signals 10 publisher sources 100/100 entity strength

Latest news

Timeline

Mon, 10 Aug 2026 16:32:50 GMTInnate Pharma price target raised to $7 from $5 at H.C. Wainwright - TipRanks
Mon, 10 Aug 2026 15:22:30 GMTSobi, Innate sign $580M pact to propel lymphoma drug through Phase III - FirstWord Pharma
Mon, 10 Aug 2026 14:03:25 GMTSwedish kiss for french Innate: Sobi backs Innate’s lacutamab as rare T-cell lymphoma program enters Phase 3 - European Biotechnology Magazine
Mon, 10 Aug 2026 13:53:58 GMTM&A Roundup: Novo Nordisk Enters AI Drug Discovery Partnership with Amazon, Innate Pharma Partners with Sobi, Innovent Enters Commercialization Agreement with Daiichi Sankyo - Pharmaceutical Executive
Mon, 10 Aug 2026 12:21:58 GMTSobi broadens portfolio through partnership with Innate Pharma - Biostock
Mon, 10 Aug 2026 11:52:53 GMTInnate Pharma S.A. and Swedish Orphan Biovitrum AB Enter Licensing Agreement for Lacutamab in T-Cell Lymphoma - marketscreener.com

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Innate Pharma Enters.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

10 distinct publisher/source names are currently connected to this entity page.